Paroxysmal Nocturnal Hemoglobinuria: Translating Pathobiology Into Modern Clinical Management

In this educational podcast discussion, Carlos M. De Castro, MD, and David Dingli, MD, PhD, FRCP, FRCPEd, FACP, FRCPath, explore paroxysmal nocturnal hemoglobinuria (PNH). They trace the evolution of treatment from early complement inhibitors to today’s expanding therapeutic options, emphasizing how these advances have transformed patient outcomes and quality of life. The conversation blends clinical insights with practical considerations for therapy selection and patient care, including:The pathogenesis of PNH and the role of complement activationLandmark therapies such as eculizumab and ravulizumabAdvances in proximal inhibitors (eg, pegcetacoplan, iptacopan, danicopan)Quality-of-life considerations, treatment personalization, and emerging therapiesPresenters:Carlos M. De Castro, MDProfessor of Medicine, DUMCDivision of Malignant Hematology and Cellular TherapyDepartment of MedicineDuke UniversityDuke Cancer InstituteDurham, North CarolinaDavid Dingli, MD, PhD, FRCP, FRCPEd, FACP, FRCPathConsultant Hematologist and Director of Bone Marrow Transplant ProgramProfessor of MedicineDivision of HematologyMayo Clinic College of Medicine and ScienceRochester, MinnesotaLink to full program:https://bit.ly/3Jtjqgr Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

There are no comments yet.

Please log in to write the first comment.